Global whole genome amplification market is anticipated to grow at a CAGR of 7.3% during the forecast period (2024-2031). Whole genome amplification promotes personalized therapy and enhanced outcomes for patients with chronic diseases by enabling a more precise and thorough investigation of the human genome. Therefore, the growing prevalence of chronic disorders across the globe has created scope for the demand of whole genome amplification kits. Therefore, key kit manufacturers are focusing on manufacturing advanced kits that are useful in treating and diagnosing chronic disorders.
Browse the full report description of “Whole Genome Amplification Market Size, Share & Trends Analysis Report by Product Type (Instruments, Kits and Reagents, and Services), by Application (Drug Discovery and Development, Disease Diagnosis, Agriculture, Veterinary Research, Forensics, and Others), and by End-User (Pharma and Biotech Companies, Contract Research Organizations, Academic Institutes, and Others) Forecast Period (2024-2031)” at https://www.omrglobal.com/industry-reports/whole-genome-amplification-market
The introduction of advanced whole genome amplification kits by major market players is likely to drive the global market. For instance, in March 2024, BioSkryb Genomics Inc. launched the new whole genome and transcriptome core kits to accelerate single cell multiomics. The new single-cell core kits leverage the power of primary template-directed amplification (PTA) in an end-to-end kitted workflow that provides amplification and library preparation reagents, sequencing adapters, and the BaseJumper bioinformatics platform. The company’s foundational PTA chemistry enables high-resolution single-cell DNA insights with 97.0% genomic coverage and 93% allelic balance. As part of these new kit configurations, total workflow time has been reduced to under eight hours for both products.
Further, in February 2024, Takara Bio announced the plans to launch two critical solutions for oncology research. These automated single-cell total RNA-seq and DNA-seq library preparation kits will provide high sample and cell throughput, less hands-on time, and the ability to capture more information than other available technologies. The Shasta Total RNA-Seq Kit will detect splicing isoforms, gene fusions, and non-polyadenylated RNAs through full-length transcriptome profiling of up to 100,000 single cells per run.
Market Coverage
• The market number available for – 2023-2031
• Base year- 2023
• Forecast period- 2024-2031
• Segment Covered-
o By Product Type
o By Application
o By End-User
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- includes GE Healthcare, Illumina, Inc., Agilent Technologies, Inc., Merck KGaA, and Thermo Fisher Scientific Inc. among others.
Key questions addressed by the report.
Global Whole Genome Amplification Market Report Segment
By Product Type
By Application
By End-User
Global Whole Genome Amplification Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/whole-genome-amplification-market